Summary
Global Markets Direct’s, ‘Les Laboratoires Servier SAS - Product Pipeline Review - 2016’, provides an overview of the Les Laboratoires Servier SAS’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Les Laboratoires Servier SAS, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Les Laboratoires Servier SAS
- The report provides overview of Les Laboratoires Servier SAS including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Les Laboratoires Servier SAS’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Les Laboratoires Servier SAS’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Les Laboratoires Servier SAS’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Les Laboratoires Servier SAS
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Les Laboratoires Servier SAS’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Les Laboratoires Servier SAS Snapshot 6
Les Laboratoires Servier SAS Overview 6
Key Information 6
Key Facts 6
Les Laboratoires Servier SAS - Research and Development Overview 7
Key Therapeutic Areas 7
Les Laboratoires Servier SAS - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Les Laboratoires Servier SAS - Pipeline Products Glance 15
Les Laboratoires Servier SAS - Late Stage Pipeline Products 15
Pre-Registration Products/Combination Treatment Modalities 15
Phase III Products/Combination Treatment Modalities 16
Les Laboratoires Servier SAS - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Les Laboratoires Servier SAS - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Les Laboratoires Servier SAS - Drug Profiles 21
(amlodipine besylate + perindopril) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ivabradine hydrochloride 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
(amlodipine besylate + indapamide + perindopril) 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
(atorvastatin calcium + perindopril) 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
(indapamide + perindopril) 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
lucitanib 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
S-38093 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
S-38844 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
S-47445 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
S-49076 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NMSP-153 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
S-055746 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Inhibit Mcl-1 for Cancer 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drugs to Inhibit Insulin-Regulated AminoPeptidase for Alzheimer’s Disease 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Monoclonal Antibodies for Cancer 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drugs for Triple Negative Breast Cancer 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules for Central Nervous System Disorders 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Les Laboratoires Servier SAS - Pipeline Analysis 41
Les Laboratoires Servier SAS - Pipeline Products by Target 41
Les Laboratoires Servier SAS - Pipeline Products by Route of Administration 43
Les Laboratoires Servier SAS - Pipeline Products by Molecule Type 44
Les Laboratoires Servier SAS - Pipeline Products by Mechanism of Action 45
Les Laboratoires Servier SAS - Recent Pipeline Updates 47
Les Laboratoires Servier SAS - Dormant Projects 52
Les Laboratoires Servier SAS - Discontinued Pipeline Products 53
Discontinued Pipeline Product Profiles 53
agomelatine 53
terutroban 53
Les Laboratoires Servier SAS - Company Statement 54
Les Laboratoires Servier SAS - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 59
Disclaimer 60
List of Tables
Les Laboratoires Servier SAS, Key Information 6
Les Laboratoires Servier SAS, Key Facts 6
Les Laboratoires Servier SAS - Pipeline by Indication, 2016 8
Les Laboratoires Servier SAS - Pipeline by Stage of Development, 2016 10
Les Laboratoires Servier SAS - Monotherapy Products in Pipeline, 2016 11
Les Laboratoires Servier SAS - Combination Treatment Modalities in Pipeline, 2016 12
Les Laboratoires Servier SAS - Partnered Products in Pipeline, 2016 13
Les Laboratoires Servier SAS - Partnered Products/ Combination Treatment Modalities, 2016 14
Les Laboratoires Servier SAS - Pre-Registration, 2016 15
Les Laboratoires Servier SAS - Phase III, 2016 16
Les Laboratoires Servier SAS - Phase II, 2016 17
Les Laboratoires Servier SAS - Phase I, 2016 18
Les Laboratoires Servier SAS - Preclinical, 2016 19
Les Laboratoires Servier SAS - Discovery, 2016 20
Les Laboratoires Servier SAS - Pipeline by Target, 2016 41
Les Laboratoires Servier SAS - Pipeline by Route of Administration, 2016 43
Les Laboratoires Servier SAS - Pipeline by Molecule Type, 2016 44
Les Laboratoires Servier SAS - Pipeline Products by Mechanism of Action, 2016 45
Les Laboratoires Servier SAS - Recent Pipeline Updates, 2016 47
Les Laboratoires Servier SAS - Dormant Developmental Projects,2016 52
Les Laboratoires Servier SAS - Discontinued Pipeline Products, 2016 53
Les Laboratoires Servier SAS, Other Locations 55
Les Laboratoires Servier SAS, Subsidiaries 55
List of Figures
Les Laboratoires Servier SAS - Pipeline by Top 10 Indication, 2016 8
Les Laboratoires Servier SAS - Pipeline by Stage of Development, 2016 10
Les Laboratoires Servier SAS - Monotherapy Products in Pipeline, 2016 11
Les Laboratoires Servier SAS - Combination Treatment Modalities in Pipeline, 2016 12
Les Laboratoires Servier SAS - Partnered Products in Pipeline, 2016 13
Les Laboratoires Servier SAS - Pipeline by Top 10 Target, 2016 41
Les Laboratoires Servier SAS - Pipeline by Route of Administration, 2016 43
Les Laboratoires Servier SAS - Pipeline by Molecule Type, 2016 44
Les Laboratoires Servier SAS - Pipeline Products by Top 10 Mechanism of Action, 2016 45
